Nebenwirkungen · Tysabri
Tysabri 300 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 12–13
HOS-113946 · Präparat HOS-094001
12 In clinical trials, herpes infections (Varicella-Zoster virus, Herpes-simplex virus) occurred slightly more frequently in natalizumab-treated patients than in placebo-treated patients. In post-marketing experience, serious, life-threatening, and sometimes fatal cases of encephalitis and meningitis caused by herpes simplex or varicella zoster have been reported in multiple sclerosis patients receiving natalizumab. The duration of treatment with natalizumab prior to onset ranged from a few months to several years (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-06T15:30:00Z · SHA-256 314c2bb2f9d46474af7df870f22ba3acb26afe4b9c18370e544b150b15ab0b88 · Passage 395bfdf7df2daf208f0877c93f22d22cf45e9a8fb84285adea396217a84cea18 · Zeichen 7921–8460 im Abschnitt